iRhythm
iRhythm's revenue rose 26.2% to $747 million in fiscal 2025. Its operating margin was −7.7%, up from −19.5% a year earlier. Free cash flow was $35 million. The diluted share count rose 2.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What iRhythm does
iRhythm provides heart-rhythm monitoring services. Its main product is a wire-free patch that a patient wears on the chest. The patch is worn for up to 14 days and records the heart's electrical signals continuously. The recordings are analyzed by the company's cloud-based software, and its technicians then prepare reports for doctors. Doctors use them to diagnose arrhythmias, which are irregular heartbeats.
iRhythm's services include long-term continuous monitoring, short-term monitoring and mobile cardiac telemetry. These are usually ordered for patients who are suspected of having infrequent, hard-to-detect or symptom-free arrhythmias, but not life-threatening ones. iRhythm provides these services from its own testing facilities, which are enrolled in Medicare.
The services are currently its only offerings, and its revenue depends on insurers and government programs paying for them. The company says its patch and software are cleared or approved in the United States, Europe and Japan. It employs about 2,400 full-time employees.
Its biggest risks, as it describes them
- Reimbursement for its services could be reduced or changed in the United States or in other countries.
- It may not be able to add commercial payors or expand coverage from the ones it has.
- Its revenue relies entirely on its iRhythm Services, which could lose market acceptance.
- Billing is complex and highly regulated, and audits or denied claims could force it to pay money back.
- Competition in remote cardiac monitoring is intense.
Income statement
iRhythm lost money in fiscal 2025: a net loss of $45 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 222 | 159 | 110 | 317 | 490 |
| Debt incl. finance leases | 10 | 35 | 35 | 646 | 650 |
| Net debt (negative means net cash) | −212 | −124 | −75 | 329 | 159 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.2x | 7.1x | 4.2x |
| Interest coverage | −85.5x | −27.5x | −34.3x | −9.0x | −4.4x |
| Current ratio | 3.5x | 3.2x | 2.1x | 5.8x | 4.6x |
| Quick ratio | 3.4x | 3.1x | 2.0x | 5.7x | 4.5x |
Cash flow
Projections
Project iRhythm's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What iRhythm says to expect
- Full year 2026: revenue and adjusted EBITDA margin
For the full year 2026, iRhythm expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5, 2026 acquisition close through year-end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%, inclusive of VitalConnect.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $56,892 of iRhythm shares on the open market, and 12 insiders sold $22.7 million, $1.9 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Daniel G. WilsonChief Financial Officer | Sold | 773 | $121.83 | $94,175 | Form 4 |
| Aug 10, 2026 | Quentin S. BlackfordPresident and CEO, Director | Sold | 26,859 | $124.65 | $3.3 million | Form 4 |
| Aug 10, 2026 | Patrick Michael MurphyCBO and CLO | Sold | 7,093 | $124.65 | $884,142 | Form 4 |
| Aug 10, 2026 | Sumi ShrishrimalEVP, Chief Risk Officer | Sold | 5,372 | $124.65 | $669,620 | Form 4 |
| Aug 3, 2026 | Chad PattersonChief Comm & Product Officer | Sold | 2,712 | $122.12 | $331,189 | Form 4 |
| Aug 3, 2026 | Julianne RoddaEVP, Chief People Officer | Sold | 2,112 | $122.12 | $257,917 | Form 4 |
| Aug 3, 2026 | Mervin SmithEVP Strategic Business Ops | Sold | 617 | $122.12 | $75,348 | Form 4 |
| Jul 2, 2026 | Minang TurakhiaChief Med/sci Ofcr EVP Advtech | Sold | 1,423 | $124.71 | $177,462 | Form 4 |
| Jul 2, 2026 | Sean Clinton FreemanEVP, Strategy & Corp Devt | Sold | 918 | $124.71 | $114,484 | Form 4 |
| Jun 2, 2026 | Sumi ShrishrimalEVP, Chief Risk Officer | Sold | 1,716 | $108.19 | $185,654 | Form 4 |
| Jun 2, 2026 | Marc Wade RosenbaumChief Accounting Officer | Sold | 729 | $108.19 | $78,871 | Form 4 |
| May 11, 2026 | Abhijit Y TalwalkarDirector | Sold plan | 5,312 | $117.93 | $626,438 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 6 of 9 | 5 of 9 |
| Rule of 40 | 1.5% | 15.0% | 30.9% |
| Altman Z'' | −3.94 | 0.39 | 0.78 |
| Accruals ratio | −16.6% | −17.1% | −12.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 2 of 9 | 6 of 9 | 5 of 9 |
Compare
Put iRhythm side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| iRhythm | FY25 | 26.2% | −7.7% | 4.6% | −12.4% | — | 5 | |
| Alphatec | FY25 | 24.9% | −10.8% | 0.4% | −14.3% | — | 5 | Compare |
| Varex Imaging | FY25 | 4.1% | −3.3% | 2.2% | −2.9% | — | 6 | Compare |
| Novocure | FY25 | 8.3% | −23.5% | −11.6% | −33.0% | — | 4 | Compare |
| Inspire Medical Systems | FY25 | 13.6% | 5.6% | 8.6% | 14.2% | −4.8x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 64 | 99 | 147 | 215 | 265 | 323 | 411 | 493 | 592 | 747 |
| Revenue growth | 77.3% | 54.7% | 48.6% | 45.7% | 23.6% | 21.7% | 27.3% | 19.9% | 20.1% | 26.2% |
| Gross profit | 43 | 71 | 108 | 162 | 195 | 214 | 282 | 332 | 408 | 527 |
| Research and development | 7 | 13 | 21 | 37 | 41 | 39 | 47 | 60 | 72 | 85 |
| Operating income | −16 | −28 | −46 | −55 | −44 | −100 | −114 | −125 | −116 | −57 |
| Net income | −21 | −30 | −50 | −55 | −44 | −101 | −116 | −123 | −113 | −45 |
| Diluted EPS (US$) | −3.95 | −1.31 | −2.11 | −2.16 | −1.58 | −3.46 | −3.88 | −4.04 | −3.63 | −1.39 |
| Diluted shares (millions) | 5 | 23 | 24 | 25 | 28 | 29 | 30 | 30 | 31 | 32 |
| Cash flow | ||||||||||
| Cash from operations | −17 | −15 | −29 | −22 | −14 | −38 | −23 | −50 | 3 | 81 |
| Capital expenditure | 3 | 4 | 5 | 20 | 14 | 28 | 30 | 40 | 34 | 46 |
| Free cash flow | −19 | −18 | −34 | −42 | −27 | −66 | −53 | −91 | −31 | 35 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 10 | 16 | 26 | 42 | 54 | 58 | 77 | 76 | 88 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 111 | 102 | 78 | 141 | 335 | 222 | 159 | 110 | 317 | 490 |
| Debt incl. finance leases | 46 | 45 | 35 | 33 | 21 | 10 | 35 | 35 | 646 | 650 |
| Total assets | 138 | 133 | 118 | 306 | 512 | 463 | 448 | 433 | 931 | 1,020 |
| Total liabilities | 46 | 54 | 65 | 171 | 170 | 184 | 208 | 223 | 840 | 867 |
| Shareholders' equity | 93 | 79 | 52 | 135 | 342 | 280 | 240 | 210 | 91 | 153 |
| Margins and ratios | ||||||||||
| Gross margin | 67.4% | 71.5% | 73.7% | 75.5% | 73.5% | 66.2% | 68.5% | 67.3% | 68.9% | 70.6% |
| Operating margin | −24.3% | −27.8% | −31.0% | −25.5% | −16.5% | −31.0% | −27.7% | −25.4% | −19.5% | −7.7% |
| Net margin | −32.6% | −30.0% | −34.2% | −25.4% | −16.5% | −31.4% | −28.3% | −25.1% | −19.1% | −6.0% |
| Free cash flow margin | −30.3% | −18.6% | −23.3% | −19.7% | −10.3% | −20.4% | −12.9% | −18.4% | −5.2% | 4.6% |
| Rule of 40 (growth + FCF margin) | 47.0% | 36.1% | 25.3% | 25.9% | 13.3% | 1.4% | 14.4% | 1.5% | 15.0% | 30.9% |
| Return on capital | — | −87.5% | −237.1% | — | — | — | −97.9% | −78.8% | −32.9% | −12.4% |
| Return on equity | — | −34.5% | −76.6% | −58.2% | −18.4% | −32.6% | −44.7% | −54.9% | −75.3% | −36.6% |
| Return on assets | −23.8% | −21.9% | −40.2% | −25.8% | −10.7% | −20.8% | −25.5% | −28.0% | −16.6% | −4.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |